Is PolyPeptide still active?

Yes, PolyPeptide is currently active.

Where is PolyPeptide registered?

PolyPeptide's registered address is Chaussée de Tubize 297, 1420 Braine-l'Alleud, Belgium.

How many employees does PolyPeptide have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2025), PolyPeptide reported 485 full-time equivalent employees.

What is PolyPeptide's annual turnover?

PolyPeptide's most recently filed annual turnover (fiscal year ending 31 Dec 2025) was €156,109,657.

Did PolyPeptide make a profit or a loss?

PolyPeptide's most recently filed annual accounts (fiscal year ending 31 Dec 2025) reported a profit of €7,243,641.

When did PolyPeptide last file annual accounts?

PolyPeptide's most recently filed annual accounts cover the fiscal year ending 31 Dec 2025.

Is PolyPeptide B Corp certified?

We have no B Corp certification on file for PolyPeptide.

Does PolyPeptide hold Fairtrade certification?

No, PolyPeptide does not currently hold Fairtrade certification.

PolyPeptide

Q: When was PolyPeptide founded?

PolyPeptide was founded on 14 Feb 2006, making it 20 years old.

Q: What does PolyPeptide do?

PolyPeptide's registered main activities are Manufacture of basic pharmaceutical products, Study, development of the production of active ingredients for drug manufacturing, and Warehousing and storage. It is also registered for 8 additional activities.

BE 0879.346.768

Copied!

NV/SA

Status

Active

Founded

14 Feb 2006

Size

Large · 485 FTE

Age

20 yrs

Main activity

Manufacture of basic pharmaceutical products

Website

polypeptide.com

Activities

11 activities

Manufacture of basic pharmaceutical productsStudy, development of the production of active ingredients for drug manufacturingWarehousing and storageManufacture of other chemical products n.e.c.Manufacture of other inorganic basic chemicalsManufacture of medicamentsManufacture of pesticides, disinfectants and other agrochemical productsManufacture of other organic basic chemicalsOther mining and quarrying n.e.c.Manufacture of other pharmaceutical productsMining of chemical and fertiliser minerals

Financials

Turnover2025

€156M+22%

Profit / Loss2025

€7.2M+328.8%

Equity2025

€104M+7.5%

2025	2024	2022	2021
€156,109,657+22%	€127,937,096+29.7%	€98,658,265+54%	€64,079,041
€7,243,641+328.8%	-€3,166,254-158.1%	€5,445,372+11.1%	€4,902,991
€103,798,985+7.5%	€96,606,018-1.6%	€98,141,387+5.8%	€92,746,689
€226,319,038+30.4%	€173,512,455+57.2%	€110,394,386+110%	€52,563,130
€87,135-71.6%	€307,106-85.1%	€2,055,745-52.2%	€4,299,398
485+3.6%	468.1+18.8%	394+24.2%	317.2
€321,876+17.8%	€273,311+9.1%	€250,402+24%	€202,015

Frequently asked questions

01What is PolyPeptide's official registered name?

PolyPeptide.

02What is PolyPeptide's enterprise number (VAT number)?

BE 0879.346.768.

03What is PolyPeptide's legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

04When was PolyPeptide founded?

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

	2025	2024	2022	2021
Income statement
	€156,109,657+22%	€127,937,096+29.7%	€98,658,265+54%	€64,079,041
	€56,767,949+11%	€51,145,302+29.5%	€39,482,583+32.5%	€29,806,293
	€15,909,259+212.7%	€5,088,260-27%	€6,970,698+19%	€5,857,922
	€24,004,600+157%	€9,341,129-32.9%	€13,915,493-2.4%	€14,254,977
	€16,018,515+902.3%	€1,598,144-87.7%	€13,019,709-1.7%	€13,247,431
	€7,243,641+328.8%	-€3,166,254-158.1%	€5,445,372+11.1%	€4,902,991
	€7,336,027+106.1%	€3,558,685+293.3%	€904,881>1000%	€5,321
Profitability
	15.4%+110.6%	7.3%-48.2%	14.1%-36.6%	22.2%
	4.6%+287.5%	-2.5%-144.8%	5.5%-27.9%	7.7%
	7.0%+312.9%	-3.3%-159.1%	5.5%+5%	5.3%
	2.2%+286.9%	-1.2%-145%	2.6%-22.8%	3.4%
Solvency
	€331,744,197+22.4%	€271,065,115+29.3%	€209,648,726+43.8%	€145,793,231
	€180,407,266+7.3%	€168,104,856+61.8%	€103,869,050+45.6%	€71,362,314
	—	—	—	€4,650
	€103,798,985+7.5%	€96,606,018-1.6%	€98,141,387+5.8%	€92,746,689
	31.3%-12.2%	35.6%-23.9%	46.8%-26.4%	63.6%
	€128,657,090+14.6%	€112,237,523+64.4%	€68,279,344+142.2%	€28,195,216
	1.24+6.7%	1.16+67%	0.70+128.9%	0.30
	€226,319,038+30.4%	€173,512,455+57.2%	€110,394,386+110%	€52,563,130
	2.18+21.4%	1.80+59.7%	1.12+98.5%	0.57
	2.72+260.3%	0.76-87%	5.82-76.5%	24.81
Liquidity
	€87,135-71.6%	€307,106-85.1%	€2,055,745-52.2%	€4,299,398
	€88,059,414+24.9%	€70,487,845-10.9%	€79,080,291+28.2%	€61,700,440
	€62,347,748+99.3%	€31,278,096+44.7%	€21,620,308+427.9%	€4,095,602
	€74,220,380+45.8%	€50,911,582+43.2%	€35,549,498+110.1%	€16,917,658
	€97,506,469+59.7%	€61,058,716+46.8%	€41,587,644+86.8%	€22,266,664
	1.55-7.5%	1.67-30.3%	2.40-12.3%	2.73
	€53,523,836+28.9%	€41,511,034-31.9%	€60,966,996+31%	€46,554,629
Efficiency
	146 days+63.4%	89 days+11.6%	80 days+242.9%	23 days
	320 days+29.2%	248 days+3.5%	240 days+50.8%	159 days
	684 days-24.4%	904 days-24.6%	1199 days-8.6%	1311 days
	0.59+55.3%	0.38+11.8%	0.34	—
Profit appropriation
	€3,338,761+12.2%	€2,976,579+3%	€2,889,967+10.4%	€2,617,698
	€60,270,197+12.9%	€53,388,738-2.8%	€54,909,370+10.4%	€49,736,267

Sources

NBB — Nationale Bank van België

	2025	2024	2022	2021
Income statement
	€156,109,657+22%	€127,937,096+29.7%	€98,658,265+54%	€64,079,041
	€56,767,949+11%	€51,145,302+29.5%	€39,482,583+32.5%	€29,806,293
	€15,909,259+212.7%	€5,088,260-27%	€6,970,698+19%	€5,857,922
	€24,004,600+157%	€9,341,129-32.9%	€13,915,493-2.4%	€14,254,977
	€16,018,515+902.3%	€1,598,144-87.7%	€13,019,709-1.7%	€13,247,431
	€7,243,641+328.8%	-€3,166,254-158.1%	€5,445,372+11.1%	€4,902,991
	€7,336,027+106.1%	€3,558,685+293.3%	€904,881>1000%	€5,321
Profitability
	15.4%+110.6%	7.3%-48.2%	14.1%-36.6%	22.2%
	4.6%+287.5%	-2.5%-144.8%	5.5%-27.9%	7.7%
	7.0%+312.9%	-3.3%-159.1%	5.5%+5%	5.3%
	2.2%+286.9%	-1.2%-145%	2.6%-22.8%	3.4%
Solvency
	€331,744,197+22.4%	€271,065,115+29.3%	€209,648,726+43.8%	€145,793,231
	€180,407,266+7.3%	€168,104,856+61.8%	€103,869,050+45.6%	€71,362,314
	—	—	—	€4,650
	€103,798,985+7.5%	€96,606,018-1.6%	€98,141,387+5.8%	€92,746,689
	31.3%-12.2%	35.6%-23.9%	46.8%-26.4%	63.6%
	€128,657,090+14.6%	€112,237,523+64.4%	€68,279,344+142.2%	€28,195,216
	1.24+6.7%	1.16+67%	0.70+128.9%	0.30
	€226,319,038+30.4%	€173,512,455+57.2%	€110,394,386+110%	€52,563,130
	2.18+21.4%	1.80+59.7%	1.12+98.5%	0.57
	2.72+260.3%	0.76-87%	5.82-76.5%	24.81
Liquidity
	€87,135-71.6%	€307,106-85.1%	€2,055,745-52.2%	€4,299,398
	€88,059,414+24.9%	€70,487,845-10.9%	€79,080,291+28.2%	€61,700,440
	€62,347,748+99.3%	€31,278,096+44.7%	€21,620,308+427.9%	€4,095,602
	€74,220,380+45.8%	€50,911,582+43.2%	€35,549,498+110.1%	€16,917,658
	€97,506,469+59.7%	€61,058,716+46.8%	€41,587,644+86.8%	€22,266,664
	1.55-7.5%	1.67-30.3%	2.40-12.3%	2.73
	€53,523,836+28.9%	€41,511,034-31.9%	€60,966,996+31%	€46,554,629
Efficiency
	146 days+63.4%	89 days+11.6%	80 days+242.9%	23 days
	320 days+29.2%	248 days+3.5%	240 days+50.8%	159 days
	684 days-24.4%	904 days-24.6%	1199 days-8.6%	1311 days
	0.59+55.3%	0.38+11.8%	0.34	—
Profit appropriation
	€3,338,761+12.2%	€2,976,579+3%	€2,889,967+10.4%	€2,617,698
	€60,270,197+12.9%	€53,388,738-2.8%	€54,909,370+10.4%	€49,736,267

2025

2024

2022

2021

Income statement

€156,109,657+22%

€127,937,096+29.7%

€98,658,265+54%

€64,079,041

€56,767,949+11%

€51,145,302+29.5%

€39,482,583+32.5%

€29,806,293

€15,909,259+212.7%

€5,088,260-27%

€6,970,698+19%

€5,857,922

€24,004,600+157%

€9,341,129-32.9%

€13,915,493-2.4%

€14,254,977

€16,018,515+902.3%

€1,598,144-87.7%

€13,019,709-1.7%

€13,247,431

€7,243,641+328.8%

-€3,166,254-158.1%

€5,445,372+11.1%

€4,902,991

€7,336,027+106.1%

€3,558,685+293.3%

€904,881>1000%

€5,321

Profitability

15.4%+110.6%

7.3%-48.2%

14.1%-36.6%

22.2%

4.6%+287.5%

-2.5%-144.8%

5.5%-27.9%

7.7%

7.0%+312.9%

-3.3%-159.1%

5.5%+5%

5.3%

2.2%+286.9%

-1.2%-145%

2.6%-22.8%

3.4%

Solvency

€331,744,197+22.4%

€271,065,115+29.3%

€209,648,726+43.8%

€145,793,231

€180,407,266+7.3%

€168,104,856+61.8%

€103,869,050+45.6%

€71,362,314

—

€4,650

€103,798,985+7.5%

€96,606,018-1.6%

€98,141,387+5.8%

€92,746,689

31.3%-12.2%

35.6%-23.9%

46.8%-26.4%

63.6%

€128,657,090+14.6%

€112,237,523+64.4%

€68,279,344+142.2%

€28,195,216

1.24+6.7%

1.16+67%

0.70+128.9%

0.30

€226,319,038+30.4%

€173,512,455+57.2%

€110,394,386+110%

€52,563,130

2.18+21.4%

1.80+59.7%

1.12+98.5%

0.57

2.72+260.3%

0.76-87%

5.82-76.5%

24.81

Liquidity

€87,135-71.6%

€307,106-85.1%

€2,055,745-52.2%

€4,299,398

€88,059,414+24.9%

€70,487,845-10.9%

€79,080,291+28.2%

€61,700,440

€62,347,748+99.3%

€31,278,096+44.7%

€21,620,308+427.9%

€4,095,602

€74,220,380+45.8%

€50,911,582+43.2%

€35,549,498+110.1%

€16,917,658

€97,506,469+59.7%

€61,058,716+46.8%

€41,587,644+86.8%

€22,266,664

1.55-7.5%

1.67-30.3%

2.40-12.3%

2.73

€53,523,836+28.9%

€41,511,034-31.9%

€60,966,996+31%

€46,554,629

Efficiency

146 days+63.4%

89 days+11.6%

80 days+242.9%

23 days

320 days+29.2%

248 days+3.5%

240 days+50.8%

159 days

684 days-24.4%

904 days-24.6%

1199 days-8.6%

1311 days

0.59+55.3%

0.38+11.8%

0.34

—

Profit appropriation

€3,338,761+12.2%

€2,976,579+3%

€2,889,967+10.4%

€2,617,698

€60,270,197+12.9%

€53,388,738-2.8%

€54,909,370+10.4%

€49,736,267

PolyPeptide

Activities

Financials

Frequently asked questions

All locations

All locations